Cargando…

Mechanistic advances in osteoporosis and anti‐osteoporosis therapies

Osteoporosis is a type of bone loss disease characterized by a reduction in bone mass and microarchitectural deterioration of bone tissue. With the intensification of global aging, this disease is now regarded as one of the major public health problems that often leads to unbearable pain, risk of bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haiwei, Luo, Yuchuan, Wang, Haisheng, Li, Feifei, Yu, Fanyuan, Ye, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175743/
https://www.ncbi.nlm.nih.gov/pubmed/37188325
http://dx.doi.org/10.1002/mco2.244
_version_ 1785040277128347648
author Wang, Haiwei
Luo, Yuchuan
Wang, Haisheng
Li, Feifei
Yu, Fanyuan
Ye, Ling
author_facet Wang, Haiwei
Luo, Yuchuan
Wang, Haisheng
Li, Feifei
Yu, Fanyuan
Ye, Ling
author_sort Wang, Haiwei
collection PubMed
description Osteoporosis is a type of bone loss disease characterized by a reduction in bone mass and microarchitectural deterioration of bone tissue. With the intensification of global aging, this disease is now regarded as one of the major public health problems that often leads to unbearable pain, risk of bone fractures, and even death, causing an enormous burden at both the human and socioeconomic layers. Classic anti‐osteoporosis pharmacological options include anti‐resorptive and anabolic agents, whose ability to improve bone mineral density and resist bone fracture is being gradually confirmed. However, long‐term or high‐frequency use of these drugs may bring some side effects and adverse reactions. Therefore, an increasing number of studies are devoted to finding new pathogenesis or potential therapeutic targets of osteoporosis, and it is of great importance to comprehensively recognize osteoporosis and develop viable and efficient therapeutic approaches. In this study, we systematically reviewed literatures and clinical evidences to both mechanistically and clinically demonstrate the state‐of‐art advances in osteoporosis. This work will endow readers with the mechanistical advances and clinical knowledge of osteoporosis and furthermore present the most updated anti‐osteoporosis therapies.
format Online
Article
Text
id pubmed-10175743
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101757432023-05-13 Mechanistic advances in osteoporosis and anti‐osteoporosis therapies Wang, Haiwei Luo, Yuchuan Wang, Haisheng Li, Feifei Yu, Fanyuan Ye, Ling MedComm (2020) Reviews Osteoporosis is a type of bone loss disease characterized by a reduction in bone mass and microarchitectural deterioration of bone tissue. With the intensification of global aging, this disease is now regarded as one of the major public health problems that often leads to unbearable pain, risk of bone fractures, and even death, causing an enormous burden at both the human and socioeconomic layers. Classic anti‐osteoporosis pharmacological options include anti‐resorptive and anabolic agents, whose ability to improve bone mineral density and resist bone fracture is being gradually confirmed. However, long‐term or high‐frequency use of these drugs may bring some side effects and adverse reactions. Therefore, an increasing number of studies are devoted to finding new pathogenesis or potential therapeutic targets of osteoporosis, and it is of great importance to comprehensively recognize osteoporosis and develop viable and efficient therapeutic approaches. In this study, we systematically reviewed literatures and clinical evidences to both mechanistically and clinically demonstrate the state‐of‐art advances in osteoporosis. This work will endow readers with the mechanistical advances and clinical knowledge of osteoporosis and furthermore present the most updated anti‐osteoporosis therapies. John Wiley and Sons Inc. 2023-05-11 /pmc/articles/PMC10175743/ /pubmed/37188325 http://dx.doi.org/10.1002/mco2.244 Text en © 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Wang, Haiwei
Luo, Yuchuan
Wang, Haisheng
Li, Feifei
Yu, Fanyuan
Ye, Ling
Mechanistic advances in osteoporosis and anti‐osteoporosis therapies
title Mechanistic advances in osteoporosis and anti‐osteoporosis therapies
title_full Mechanistic advances in osteoporosis and anti‐osteoporosis therapies
title_fullStr Mechanistic advances in osteoporosis and anti‐osteoporosis therapies
title_full_unstemmed Mechanistic advances in osteoporosis and anti‐osteoporosis therapies
title_short Mechanistic advances in osteoporosis and anti‐osteoporosis therapies
title_sort mechanistic advances in osteoporosis and anti‐osteoporosis therapies
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175743/
https://www.ncbi.nlm.nih.gov/pubmed/37188325
http://dx.doi.org/10.1002/mco2.244
work_keys_str_mv AT wanghaiwei mechanisticadvancesinosteoporosisandantiosteoporosistherapies
AT luoyuchuan mechanisticadvancesinosteoporosisandantiosteoporosistherapies
AT wanghaisheng mechanisticadvancesinosteoporosisandantiosteoporosistherapies
AT lifeifei mechanisticadvancesinosteoporosisandantiosteoporosistherapies
AT yufanyuan mechanisticadvancesinosteoporosisandantiosteoporosistherapies
AT yeling mechanisticadvancesinosteoporosisandantiosteoporosistherapies